AGT-1

Drug Profile

AGT-1

Latest Information Update: 04 Nov 2003

Price : $50

At a glance

  • Originator Advanced Biotherapy
  • Developer Advanced Biotherapy; Brown University Medical School; GroupMed CRO; Russian Academy of Medical Sciences; Russian State Medical University
  • Class Antibodies
  • Mechanism of Action Immunosuppressants; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Multiple sclerosis in Russia (unspecified route)
  • 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Rheumatoid arthritis in Russia (Injection)
  • 04 Nov 2003 Discontinued - Clinical-Phase-Unknown for Systemic lupus erythematosus in Russia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top